Drugs in Dev.
Genetic Disease
Discovery
Netherlands 
Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Undisclosed
Therapeutic Area : Genetic Disease
Study Phase : Discovery
Sponsor : Ono Pharmaceutical
Deal Size : Undisclosed
Deal Type : Licensing Agreement
Scenic Biotech Signs Agreement with Ono Pharma
Details : Through the licensing deal, an undisclosed product in the miscellaneous category will be utilized to address genetic disorders.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Undisclosed
January 07, 2026
Lead Product(s) : Undisclosed
Therapeutic Area : Genetic Disease
Highest Development Status : Discovery
Sponsor : Ono Pharmaceutical
Deal Size : Undisclosed
Deal Type : Licensing Agreement

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Undisclosed
Therapeutic Area : Genetic Disease
Study Phase : Discovery
Sponsor : Eli Lilly
Deal Size : $1,300.0 million
Deal Type : Collaboration
ProQR Announces Axiomer® RNA Editing Licensing and Research Collaboration with Lilly
Details : This collaboration with Lilly, is an important validation for Axiomer® RNA editing platform of ProQR, which enables the editing of single nucleotides in RNA in a highly targeted and specific manner.
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : $50.0 million
September 08, 2021
Lead Product(s) : Undisclosed
Therapeutic Area : Genetic Disease
Highest Development Status : Discovery
Sponsor : Eli Lilly
Deal Size : $1,300.0 million
Deal Type : Collaboration

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Undisclosed
Therapeutic Area : Genetic Disease
Study Phase : Discovery
Sponsor : Yarrow Biotechnology
Deal Size : Undisclosed
Deal Type : Collaboration
Details : Under the terms of the agreement, Yarrow Biotechnology, a company newly created by RTW, has in-licensed rights to ProQR’s antisense oligonucleotide technology to develop and commercialize potential therapies for an undisclosed non-ophthalmic target.
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : $115.0 million
May 04, 2021
Lead Product(s) : Undisclosed
Therapeutic Area : Genetic Disease
Highest Development Status : Discovery
Sponsor : Yarrow Biotechnology
Deal Size : Undisclosed
Deal Type : Collaboration

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Undisclosed
Therapeutic Area : Genetic Disease
Study Phase : Discovery
Sponsor : Genentech
Deal Size : $375.0 million
Deal Type : Collaboration
Scenic Biotech Enters into Genetic Modifier Collaboration with Genentech
Details : Under the terms of the agreement, Scenic will utilize its Cell-Seq platform and its data warehouse of genetic modifiers to identify drug targets in multiple therapeutic areas.
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Undisclosed
September 21, 2020
Lead Product(s) : Undisclosed
Therapeutic Area : Genetic Disease
Highest Development Status : Discovery
Sponsor : Genentech
Deal Size : $375.0 million
Deal Type : Collaboration
